ArticleDiscover oncology2025
Investigating the effect of stearoyl-coenzyme desaturase 1 Inhibition on inflammatory and anti-inflammatory patterns in luminal A breast cancer patients' peripheral blood mononuclear cells.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Elevated Plasma Monounsaturated Fatty Acids and Their Associations with Disease Activity, Adiposity, and Sex in Patients with Rheumatoid Arthritis: A Cross-Sectional Study.medRxiv : the preprint server for health sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
purposeBreast cancer (BC) is the most prevalent female cancer globally. A key feature of cancer cells is a remarkable alteration in lipid composition, notably an enrichment in monounsaturated fatty acids. This change results from the upregulated expression of enzymes involved in fatty acid metabolism, such as stearoyl-CoA desaturase 1 (SCD1), which may affect immune-related responses. PATIENTS AND
methodsIn the present study, 20 patients with luminal A BC and 20 healthy controls were included based on diagnostic criteria. Then, 10 ml of peripheral blood was retrieved from each participant, and peripheral blood mononuclear cells (PBMCs) were isolated, pooled, and cultured in RPMI 1640 medium. The treatment and control groups were then treated with 3 µM of the SCD1 chemical inhibitor and DMSO, respectively, for 48 h. The alteration in inflammatory markers IL-17 and TNF-α, anti-inflammatory markers IL-10 and TGF-β, inflammatory differentiation markers RORγt, and anti-inflammatory differentiation markers FOXP3 were assessed through Real-time PCR. Furthermore, the amount of the respective protein was measured through the enzyme-linked immunosorbent assay method.
resultsChemical inhibition of SCD1 resulted in a significant downregulation of IL-17/TNF-α and upregulation of IL-10/TGF-β expression in the patient group. Additionally, a significant upregulation of FOXP3 was observed in BC patients after SCD1 inhibition. RORγt expression was also decreased in healthy individuals after SCD1 inhibition, with no effect on the patient group.
conclusionThe results of this study suggest that SCD1 may act as a potential biomarker in the context of immune response.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.